Brief: Hansa Biopharma Says Imlifidase Successfully Meets Primary Endpoint In Pivotal Us Phase 3 Confides Trial In Kidney Transplantation
24/09/2025 17:23
Sept 24 (Reuters) - Hansa Biopharma AB HNSA.ST: IMLIFIDASE SUCCESSFULLY MEETS PRIMARY ENDPOINT IN PIVOTAL US PHASE 3 CONFIDES TRIAL IN KIDNEY TRANSPLANTATION HANSA BIOPHARMA AB - BLA SUBMISSION PLANNED FOR END OF 2025 HANSA BIOPHARMA AB - IMLIFIDASE WELL TOLERATED WITH CONSISTENT SAFETY PROFILE Source text: ID:nWkr2qpf0T Further company coverage: HNSA.ST ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hansa Biopharma AB
See all newsBrief: Hansa Biopharma Q3 Rev Up At SEK 143 Mln
Sweden's Hansa Biopharma Q3 revenue surges on SERB license deal
Brief: Hansa Biopharma Q3 Net Income SEK -178.5 Million
Brief: Hansa Biopharma Announces Positive Idefirix Paes Results Presented In The High-Impact Clinical Trials Session At Asn Kidney Week
Brief: Hansa Biopharma Submits IND Application To FDA For HNSA-5487 In GBS